Beovu

Beovu (Brolucizumab) is an intravitreal injection used to treat wet age-related macular degeneration (AMD). This medication helps slow vision loss by targeting vascular endothelial growth factor (VEGF).

Beovu is primarily used for the treatment of wet age-related macular degeneration, a condition that can lead to vision loss. It works by inhibiting VEGF, which can help reduce abnormal blood vessel growth in the retina. Patients often wonder, 'What is Beovu used for?' and the answer is that it is designed to slow the progression of vision loss associated with wet AMD.

Common effects of Beovu may include eye redness, eye pain, and floaters. Some patients may also experience increased eye pressure or inflammation. These effects are generally mild to moderate and should be discussed with a healthcare provider.

Beovu should be administered by a healthcare professional experienced in intravitreal injections. Patients should be monitored for signs of inflammation or infection. It is important to follow all safety guidelines provided by the healthcare provider.

Beovu may interact with other medications, particularly those that affect the immune system or blood vessels. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.